

The Medical Letter[®]

on Drugs and Therapeutics

Volume 64

Published online October 31, 2022

Online
Article

IN THIS ISSUE

COVID-19 Update: Novavax Vaccine Authorized for Booster Immunization

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited.

Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

**For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769**

The Medical Letter®

on Drugs and Therapeutics

Volume 64

Published online October 31, 2022

Online
Article

IN THIS ISSUE

Novavax Vaccine Authorized for Booster Immunization p 1

COVID-19 UPDATE

Novavax Vaccine Authorized for Booster Immunization

The FDA has expanded its Emergency Use Authorization for the adjuvanted protein subunit COVID-19 vaccine manufactured by Novavax to include its use as a first booster dose in adults who completed a primary series with any COVID-19 vaccine ≥ 6 months previously and are unable or unwilling to receive a booster dose of a bivalent mRNA vaccine. The Novavax vaccine is not authorized for use in persons who have received a booster dose of any other COVID-19 vaccine.¹

CLINICAL STUDIES – In an unpublished, open-label, longitudinal immunogenicity trial (summarized in the FDA Fact Sheet), 243 subjects who had completed a primary series with the Novavax COVID-19 vaccine ≥ 6 months previously and had no evidence of prior SARS-CoV-2 infection were given a booster dose of the Novavax vaccine. At 28 days after the booster dose, the geometric mean 50% anti-SARS-CoV-2 neutralizing antibody titer level was higher than it was at 14 days after completion of the primary series (5075.6 vs 1505.7; geometric mean ratio 3.4 [95% CI 2.8-4.0]), and titer levels were ≥ 4 -fold higher than they were before booster immunization in 85% of subjects.²

In one cohort of a randomized, double-blind immunogenicity study in adults ≥ 30 years old with no evidence of prior SARS-CoV-2 infection, 232 subjects who had completed a primary series with the Pfizer/BioNTech COVID-19 vaccine (*Comirnaty*) ≥ 84 days previously were given either a booster dose of the Novavax vaccine or a meningococcal vaccine. The geometric mean 50% anti-SARS-CoV-2 neutralizing antibody titer level 28 days after vaccination was ~ 5 fold higher in the Novavax group than in the control group.³

ADVERSE EFFECTS – Adverse effects with a booster dose of the Novavax vaccine in adults appear to be similar to those with a second primary-series dose.⁴ Myocarditis was reported in one patient who received a booster dose in the longitudinal study. Other serious adverse effects such as autoimmune hepatitis, local muscle edema and cellulitis, and venous thromboembolism have been reported following booster immunization with the Novavax vaccine, but causal relationships have not been established.²

DOSAGE AND ADMINISTRATION – The recommended booster dosage of the Novavax vaccine is 0.5 mL (5 mcg of vaccine with 50 mcg of adjuvant) injected intramuscularly ≥ 6 months after completion of a primary series with any COVID-19 vaccine.

RECOMMENDATIONS – CDC guidelines recommend that adults who have completed a primary series with any COVID-19 vaccine receive a booster dose of either the bivalent Pfizer vaccine or the bivalent Moderna vaccine (*Spikevax*) ≥ 2 months after their most recent monovalent vaccine dose.⁵ The Novavax vaccine may be given as a booster dose to adults who have completed a primary series of any COVID-19 vaccine ≥ 6 months previously, have not received a COVID-19 vaccine booster dose of any type, and are unable or unwilling to receive a booster dose of either the bivalent Pfizer vaccine or the bivalent Moderna vaccine.⁶ ■

1. FDA News Release. FDA Roundup: October 21, 2022. Available at: <https://bit.ly/3FbuAC5>. October 31, 2022.
2. FDA. Fact sheet for health care providers administering vaccine (vaccination providers). Emergency Use Authorization (EUA) of the Novavax vaccine, adjuvanted to prevent coronavirus disease 2019 (COVID-19). October 31, 2022. Available at: <https://bit.ly/3o702aV>. November 10, 2022.
3. APS Munro et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. *Lancet* 2021; 398:2258.

4. COVID-19 Update: FDA authorizes Novavax COVID-19 vaccine. *Med Lett Drugs Ther* 2022; 64:121.
5. COVID-19 Update: Bivalent Pfizer and Moderna COVID-19 vaccines for booster immunization. *Med Lett Drugs Ther* 2022; 64:159.
6. CDC. Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. October 19, 2022. Available at: <https://bit.ly/3KgPdXl>. October 31, 2022.

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT, EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhM, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli
EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The Medical Letter, Inc. do not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:

The Medical Letter, Inc.
 145 Huguenot St. Ste. 312
 New Rochelle, NY 10801-7537
www.medicalletter.org

Customer Service:

Call: 800-211-2769 or 914-235-0500
 Fax: 914-632-1733
 E-mail: custserv@medicalletter.org

Permissions:

To reproduce any portion of this issue, please e-mail your request to: permissions@medicalletter.org

Subscriptions (US):

1 year - \$159; 2 years - \$298;
 3 years - \$398. \$65 per year
 for students, interns, residents,
 and fellows in the US and Canada.
 Reprints - \$45 per issue or article

Site License Inquiries:

E-mail: SubQuote@medicalletter.org
 Call: 800-211-2769
 Special rates available for bulk
 subscriptions.